Get the Stockscreener App
0.6096
0.08%
-0.0005
Pre-market:
.59
-0.0196
-3.22%
Pavmed Inc stock is traded at $0.6096, with a volume of 101.65K.
It is down -0.08% in the last 24 hours and down -7.50% over the past month.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
See More
Previous Close:
$0.6101
Open:
$0.61
24h Volume:
101.65K
Relative Volume:
0.48
Market Cap:
$8.32M
Revenue:
$4.03M
Net Income/Loss:
$24.32M
P/E Ratio:
-0.1417
EPS:
-4.3008
Net Cash Flow:
$-45.76M
1W Performance:
-9.01%
1M Performance:
-7.50%
6M Performance:
-65.75%
1Y Performance:
-71.78%
1-Day Range:
$0.5792
$0.6399
1-Week Range:
$0.5792
$0.699
52-Week Range:
$0.5719
$2.84
Pavmed Inc Stock (PAVM) Company Profile
Name
Pavmed Inc
Sector
Industry
Phone
(212) 949-4319
Address
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.6096 | 8.32M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-05-20 | Initiated | Ascendiant Capital Markets | Buy |
| Jun-28-18 | Initiated | Maxim Group | Buy |
Pavmed Inc Stock (PAVM) Latest News
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test - PR Newswire
Lucid Diagnostics Executes First Concierge Medicine Contract wit - GuruFocus.com
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Pri - GuruFocus.com
PAVmed CEO to Reveal Growth Strategy and Q4 Results in Upcoming Investor Call - StockTitan
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 - Quantisnow
PAVmed, Inc. to Host Earnings Call - ACCESS Newswire
Lucid Diagnostics secures $15.3 million in stock offering By Investing.com - Investing.com Australia
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering - GuruFocus.com
Lucid Diagnostics secures $15.3 million in stock offering - Investing.com
Has Lucid Diagnostics Secured Enough Capital? $15.3M Raised at $1.10 Per Share - StockTitan
Lucid Diagnostics secures $15.3 million in stock sale By Investing.com - Investing.com Australia
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering - The Eastern Progress Online
SEC Form 424B5 filed by Lucid Diagnostics Inc. - Quantisnow
Insulet (NASDAQ:PODD) & PAVmed (NASDAQ:PAVM) Head-To-Head Review - Defense World
Lucid Diagnostics Announces $15.3 Million Registered Direct Offe - GuruFocus.com
Lucid Diagnostics ends "at the market" equity offering By Investing.com - Investing.com South Africa
Lucid Diagnostics ends "at the market" equity offering - Investing.com India
Lucid Diagnostics secures $15.3 million in stock sale - Investing.com
Lucid Diagnostics Raises $15.3 Million Through Common Stock Offering at $1.10 Per Share - StockTitan
PAVmed Inc. (NASDAQ:PAVM) Short Interest Update - Defense World
Tasso Partners Reports 18.9% Passive Stake In PAVmed As Of Feb 21SEC Filing - Marketscreener.com
Can Lucid's Cancer Test Reach Millions More Patients? NIH Invests $8M to Find Out - StockTitan
Renowned Investigators Awarded $8 Million NIH Grant to Study Luc - GuruFocus.com
Lucid Diagnostics meets Nasdaq minimum bid price rule By Investing.com - Investing.com Australia
Lucid Diagnostics Restores Nasdaq Listing Compliance - Nasdaq
Lucid Diagnostics meets Nasdaq minimum bid price rule - Investing.com
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire
PAVmed, Veris Health complete private placement financing - Medical Buyer
PAVmed and Subsidiary Veris Health Complete Private Placement Financing - PR Newswire
Can This New Cancer Monitoring Device Transform Patient Care? PAVmed Secures Crucial Funding - StockTitan
Lucid Diagnostics secures concierge medicine contract By Investing.com - Investing.com Nigeria
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Lucid Diagnostics secures concierge medicine contract - Investing.com
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health - Nasdaq
PAVmed regains Nasdaq compliance - MSN
PAVmed Regains Compliance with Nasdaq Listing Standards**WASHINGTON, DC—In a recent 8-K filing with the Securities and Exchange Commission, PAVmed Inc. (NASDAQ: PAVM) announced that it has successfully regained compliance with the Nasda - Defense World
PAVmed regains compliance with Nasdaq Capital Market’s CLS - Medical Buyer
PAVMPavmed Latest Stock News & Market Updates - StockTitan
PAVmed regains Nasdaq compliance with stockholders' equity By Investing.com - Investing.com Canada
PAVmed Regains Compliance With Nasdaq Listing Standards -February 18, 2025 at 10:07 am EST - Marketscreener.com
PAVmed regains Nasdaq compliance with stockholders’ equity By Investing.com - Investing.com Nigeria
PAVmed regains Nasdaq compliance with stockholders' equity - Investing.com
PAVmed regains Nasdaq compliance with equity boost By Investing.com - Investing.com South Africa
Innovative Tech Company Surges Forward: PAVmed Triumphs in Nasdaq Compliance - Smartphone Magazine
PAVmed regains Nasdaq compliance with equity boost - Investing.com India
Navigating the High Seas of Market Compliance: PAVmed’s Resilient Return - Mi Valle
PAVmed Triumphs on Nasdaq: A Medical Tech Comeback Story - Jomfruland.net
Critical Victory: PAVmed's Strategic Moves Save Nasdaq StatusFull Details Inside - StockTitan
SI-BONE (NASDAQ:SIBN) vs. Lucid Diagnostics (NASDAQ:LUCD) Head to Head Survey - Defense World
PAVmed stock touches 52-week low at $0.57 amid market challenges - MSN
Lucid Diagnostics (NASDAQ:LUCD) vs. Insulet (NASDAQ:PODD) Head-To-Head Review - Defense World
Pavmed Inc Stock (PAVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):